SAN DIEGO, March 26, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it will begin commercializing its recently
expanded pathology partnership platform, EmpowerTC, to urology and
uropathology practices. Biocept has expanded the capability of
EmpowerTC to perform biomarker tests that can aid physicians and
pathologists in the management of patients diagnosed with prostate
cancer. Such tests include the androgen receptor splice variant,
AR-V7, PTEN, and other cancer biomarker tests, which can
help physicians determine treatment pathways and provide prognostic
information with regards to aggressiveness of disease.
"The new uro-oncology biomarkers included in Biocept's EmpowerTC
service enables my pathology team to use cutting-edge liquid biopsy
technologies, which can be useful in our practice when making
treatment decisions for our patients with prostate cancer," said
Michael P. Zahalsky, MD, Founder and
President of Z Urology in Coral Springs,
Florida. "Liquid biopsy testing is becoming an important
tool for personalizing cancer treatment, and we look forward to
utilizing EmpowerTC to harness predictive and prognostic biomarker
information from a simple blood sample."
"We are excited to expand our commercial offering into the
urology market segment with the new biomarkers incorporated into
our EmpowerTC service," said Michael
Nall, President and CEO of Biocept. "We believe that
our pathology partnership platform offers urologists and
uro-pathologists a unique solution to evaluate and treat their
patients diagnosed with prostate cancer, which further
distinguishes Biocept from other commercial liquid biopsy
services."
About Liquid Biopsy Biomarker Detection for Prostate
Cancer
Prostate cancer is a leading cause of cancer death in the
United States with 31,620 deaths and 174,650 new cases
estimated for 2019.1 The disease is diagnosed from
pathologic evaluation (Gleason score) of needle-based tissue
biopsies, and biopsy tissue is used to determine prognosis and
guide treatment. However, prostate cancer is a multifocal disease
and a needle biopsy often misses a potentially relevant tumor;
there can also be significant variation within pathologic
evaluation of a specific tumor.2,3 Liquid-based biopsy
biomarker detection may address tumor heterogeneity and enable
more-informed prognosis.
Patients who present with advanced disease typically receive
chemical castration with androgen deprivation therapy (ADT) or
surgical castration as initial treatment to reduce androgen-driven
tumor growth. However, most prostate cancer patients acquire
resistance to the initial treatment, thus progressing to a
castration-resistant disease
state.4 Prognostic markers can help suggest
the patient's overall outcome, such as the probability of
biochemical recurrence or metastasis, and prognostic markers may be
useful to guide patient management. Predictive markers aim to
evaluate the likelihood of benefit from a specific clinical
intervention. Liquid biopsy provides the ability
to assess both prognostic and predictive biomarkers such as
androgen receptor (AR) overexpression, circulating tumor cell (CTC)
enumeration, the genomic biomarkers PTEN, MYC, C-met,
EGFR amplification and AR splice variant-7 (AR-V7), which
offer promise in meeting this important medical need.
About Biocept's Pathology Partnership Offering
Biocept's EmpowerTC offering provides liquid biopsy services to
pathologists, thereby extending our partners' breadth of laboratory
offerings. This offering empowers pathologists to combine their
skills, knowledge and experience with Biocept's patented and
proprietary liquid biopsy platform technology. For more information
about Biocept's EmpowerTC testing service, please contact Biocept
Customer Services at 888.332.7729.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with information for
treating and monitoring patients diagnosed with cancer. The
Company's patented Target Selector™ liquid biopsy technology
platform captures and analyzes tumor-associated molecular markers
in both CTCs and in plasma (ctDNA). With thousands of tests
performed, the platform has demonstrated the ability to identify
cancer mutations and alterations to inform physicians about a
patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the potential clinical
utility of our proprietary technology platform and the utility
and commercial success of our EmpowerTC offering, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
References:
|
[1]
|
Cancer Statistics
Center." American Cancer Society,
www.cancerstatisticscenter.org. Accessed 18 March 2019.
|
[2]
|
Corcoran, NM et al.
Underestimation of Gleason score at prostate biopsy reflects
sampling error in lower volume tumours. BJU Int. 2012
Mar;109(5):660-4.
|
[3]
|
Perlis, N et al.
Limitations in Predicting Organ Confined Prostate Cancer in
Patients with Gleason Pattern 4 on Biopsy: Implications for Active
Surveillance. J Urol. 2017 Jan;197(1):75-83.
|
[4]
|
Harris WP,
et al. Androgen deprivation therapy: progress in understanding
mechanisms of resistance and optimizing androgen depletion. Nat
Clin Pract Urol 2009; 6: 76–85.
|
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-broadens-commercial-focus-of-its-target-selector-liquid-biopsy-platform-to-include-urology-market-segment-300818294.html
SOURCE Biocept, Inc.